Top

Journal of Gastrointestinal Cancer

Published in:

01-03-2017 | Letter to the Editor

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

Authors: CATC Lunenburg, JJ Swen, H-J Guchelaar, H Gelderblom

Published in: Journal of Gastrointestinal Cancer | Issue 1/2017

Excerpt

Dear Editor, …

Kodali S, Bathini V, Rava P, Tipirneni E. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-fluorouracil. J Gastrointest Cancer. 2016

Terrazzino S, Cargnin S, Del RM, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14 + 1G > A and 2846A > T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14(11):1255–72.CrossRefPubMed

Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32(10):1031–9.CrossRefPubMedPubMedCentral

Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227–34.CrossRefPubMed

Lunenburg CA, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40–8.CrossRefPubMed

Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.CrossRefPubMed

Swen JJ, Nijenhuis M, De BA, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.CrossRefPubMed

Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640–5.CrossRefPubMedPubMedCentral

Background information pharmacogenetics—dihydropyrimidine dehydrogenase (DPD). 2016; Available from: http://www.kennisbank.knmp.nl. 2015

10.

Magnani E, Farnetti E, Nicoli D, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417–23.CrossRefPubMed

11.

Bank PCD, Guchelaar HJ, Swen JJ. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2014;9(4):481–2.CrossRefPubMed

Title: Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil
Authors: CATC Lunenburg
JJ Swen
H-J Guchelaar
H Gelderblom
Publication date: 01-03-2017
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 1/2017
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-016-9908-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy